Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus

Journal of Clinical Investigation

Volumn 114, Issue 7, 2004, Pages 877-883

  Rother, Kristina I ^a   Harlan, David M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INSULIN; RAPAMYCIN; TACROLIMUS;

ANEMIA; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CANCER RISK; DIABETOGENESIS; DIARRHEA; DRUG HYPERSENSITIVITY; FATIGUE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KIDNEY DISEASE; LIPID BLOOD LEVEL; MORTALITY; MOUTH ULCER; NEPHROTOXICITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMOKING; SURGICAL TECHNIQUE; TREMOR; WEIGHT REDUCTION;

AGE FACTORS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; TREATMENT OUTCOME;

EID: 9644294263     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200423235     Document Type: Review

References (87)

1. Hirshberg, B., Rother, K.I., Digon, B.J., III, Venstrom, J., and Harlan, D.M. 2003. State of the art: islet transplantation for the cure of type 1 diabetes mellitus. Rev. Endocr. Metab. Disord. 4:381-389.
2. Shapiro, A.M., et al. 2000. Islet transplantation in seven patients with type I diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343:230-238.
3. Hirshberg, B., Rother, K.I., and Harlan, D.M. 2003. Islet transplantation: where do we stand now? Diabetes Metab. Res. Rev. 19:175-178.
4. Hirshberg, B., et al. 2003. Solitary islet transplantation for type 1 diabetes mellitus using steroid sparing immunosuppression: the NIH experience. Diabetes Care. 26:3288-3295.
5. Hovind, P., et al. 2003. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 26:1258-1264.
6. Nordwall, M., Bojestig, M., Arnqvist, H.J., and Ludvigsson, J. 2004. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes - the Linkoping Diabetes Complications Study. Diabetologia. 47:1266-1272.
7. Nishimura, R., et al. 2001. Mortality trends in type 1 diabetes. The Allegheny County (Pennsylvania) Registry 1965-1999. Diabetes Care. 24:823-827.
8. Palmer, J.P., et al. 2004. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 53:250-264.
9. Lohr, M., and Kloppel, G. 1987. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin-dependent) diabetes mellitus and microangiopathy. Diabetologia. 30:757-762.
10. Madsbad, S. 1983. Factors of importance for residual beta-cell function in type I diabetes mellitus. A review. Acta Med. Scand. Suppl. 671:61-67.
11. Eff, C., Faber, O., and Deckert, T. 1978. Persistent insulin secretion, assessed by plasma C-peptide estimation in long-term juvenile diabetics with a low insulin requirement. Diabetologia. 15:169-172.
12. Steffes, M. W., Sibley, S., Jackson, M., and Thomas, W. 2003. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 26:832-836.
13. Williams, P.W. 1894. Notes on diabetes, treated with extract and by grafts of sheep's pancreas. BMJ. 2:1303-1304.
14. Karges, B., et al. 2004. Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment. Diabetes Care. 27:1207-1208.
15. Ilic, S., Jovanovic, L., and Wollitzer, A.O. 2000. Is the paradoxical first trimester drop in insulin requirement due to an increase in C-peptide concentration in pregnant Type I diabetic women? Diabetologia. 43:1329-1330.
16. Benedum, J. 1999. The early history of endocrine cell transplantation. J. Mol. Med. 77:30-35.
17. Pybus, F.C. 1924. Notes on suprarenal and pancreatic grafting. Lancet. 550-551.
18. Ballinger, W.F., and Lacy, P.E. 1972. Transplantation of intact pancreatic islets in rats. Surgery. 72:175-186.
19. Najarian, J.S., et al. 1977. Human islet transplantation: a preliminary report. Transplant. Proc. 9:233-236.
20. Largiader, F., Kolb, E., and Binswanger, U. 1980. A long-term functioning human pancreatic islet allotransplant. Transplantation. 29:76-77.
21. Scharp, D.W., et al. 1990. Insulin independence after islet transplantation into type 1 diabetic patient. Diabetes. 39:515-518.
22. Ricordi, C., Lacy, P.E., Finke, E.H., Olack, B.J., and Scharp, D.W. 1988. Automated method for isolation of human pancreatic islets. Diabetes. 37:413-420.
23. Flattem, N., et al. 2001. Alpha- and beta-cell responses to small changes in plasma glucose in the conscious dog. Diabetes. 50:367-375.
24. Brissova, M., et al. 2004. Intraislet endothelial cells contribute to revascularization of transplanted pancreatic islets. Diabetes. 53:1318-1325.
25. Hering, B.J., et al. 2004. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am. J. Transplant. 4:390-401.
26. Shapiro, A.M., and Ricordi, C. 2004. Unraveling the secrets of single donor success in islet transplantation. Am. J. Transplant. 4:295-298.
27. Beattie, G.M., et al. 2002. A novel approach to increase human islet cell mass while preserving beta-cell function. Diabetes. 51:3435-3439.
28. Beattie, G.M., Hayek, A., and Levine, F. 2000. Growth and genetic modification of human beta-cells and beta-cell precursors. Genet. Eng. 22:99-120.
29. Hayek, A., and Beattie, G.M. 2002. Alternatives to unmodified human islets for transplantation. Curr. Diab. Rep. 2:371-376.
30. Bonner-Weir, S., et al. 2000. In vitro cultivation of human islets from expanded ductal tissue. Proc. Natl. Acad. Sci. U. S. A. 97:7999-8004.
31. Dutta, S., et al. 2001. PDX:PBX complexes are required for normal proliferation of pancreatic cells during development. Proc. Natl. Acad. Sci. U. S. A. 98:1065-1070.
32. Sharma, A., et al. 1999. The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. Diabetes. 48:507-513.
33. Dor, Y., Brown, J., Martinez, O.I., and Melton, D.A. 2004. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature. 429:41-46.
34. Kolber-Simonds, D., et al. 2004. Production of alpha-1,3- galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc. Natl. Acad. Sci. U. S. A. 101:7335-7340.
35. Blusch, J.H., Patience, C., and Martin, U. 2002. Pig endogenous retroviruses and xenotransplantation. Xenotransplantation. 9:242-251.
36. Magre, S., Takeuchi, Y., and Bartosch, B. 2003. Xenotransplantation and pig endogenous retroviruses. Rev. Med. Virol. 13:311-329.
37. Quinn, G., et al. 2004. Genotyping of porcine endogenous retroviruses from a family of miniature swine. J. Virol. 78:314-319.
38. Martin, U., et al. 2000. Productive infection of primary human endothelial cells by pig endogenous retrovirus (PERV). Xenotransplantation. 7:138-142.
39. Tucker, A., et al. 2002. The production of transgenic pigs for potential use in clinical xenotransplantation: microbiological evaluation. Xenotransplantation. 9:191-202.
40. Hori, Y., et al. 2002. Growth inhibitors promote differentiation of insulin-producing tissue from embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 99:16105-16110.
41. Lumelsky, N., et al. 2001. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science. 292:1389-1394.
42. Rajagopal, J., Anderson, W.J., Kume, S., Martinez, O.I., and Melton, D.A. 2003. Insulin staining of ES cell progeny from insulin uptake. Science. 299:363.
43. Ianus, A., Holz, G.G., Theise, N.D., and Hussain, M.A. 2003. In vivo derivation of glucose-competent pancreatic endocrine cells from bone marrow without evidence of cell fusion. J. Clin. Invest. 111:843-850. doi:10.1172/JCI200316502.
44. Kodama, S., Kuhtreiber, W., Fujimura, S., Dale, E.A., and Faustman, D.L. 2003. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science. 302:1223-1227.
45. Bennet, W., Groth, C.G., Larsson, R., Nilsson, B., and Korsgren, O. 2000. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups. J. Med. Sci. 105:125-133.
46. Johansson, U., Olsson, A., Gabrielsson, S., Nilsson, B., and Korsgren, O. 2003. Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem. Biophys. Res. Commun. 308:474-479.
47. Moberg, L., et al. 2002. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 360:2039-2045.
48. Dombrowski, F., Klingmuller, D., and Pfeifer, U. 1998. Insulinomas derived from hyperplastic intra-hepatic islet transplants. Am. J. Pathol. 152:1025-1038.
49. Marx, J. 2003. Cancer research. Mutant stem cells may seed cancer. Science. 301:1308-1310.
50. Ryan, E.A., et al. 2002. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes. 51:2148-2157.
51. Digon, B.J., III, Rother, K.I., Hirshberg, B., and Harlan, D.M. 2003. Sirolimus-induced interstitial pneumonitis in an islet transplant recipient. Diabetes Care. 26:3191.
52. The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:977-986.
53. UK Prospective Diabetes Study Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:837-853.
54. UK Prospective Diabetes Study Group. 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 317:703-713.
55. Adler, A.I., et al. 2000. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 321:412-419.
56. Collins, R., Armitage, J., Parish, S., Sleigh, P., and Peto, R. 2003. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 361:2005-2016.
57. Orchard, T.J., Lloyd, C.E., Maser, R.E., and Kuller, L.H. 1996. Why does diabetic autonomie neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study.Diabetes Res. Clin. Pract. 34(Suppl.):S165-S171.
58. Soedamah-Muthu, S.S., et al. 2004. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care. 27:530-537.
59. Allen, K.V., and Walker, J.D. 2003. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care. 26:2389-2391.
60. Sarnak, M.J., et al. 2003. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 108:2154-2169.
61. Strippoli, G.F., et al. 2003. Clinical and therapeutic aspects of diabetic nephropathy. J. Nephrol. 16:487-499.
62. Mazur, M.J., et al. 2004. Decline in native renal function early after bladder-drained pancreas transplantation alone. Transplantation. 77:844-849.
63. Ojo, A.O., et al. 2003. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349:931-940.
64. Rubel, J.R., Milford, E.L., McKay, D.B., and Jarcho, J.A. 2004. Renal insufficiency and end-stage renal disease in the heart transplant population. J. Heart Lung Transplant. 23:289-300.
65. Venstrom, J.M., et al. 2003. Pancreas transplantation decreases survival for patients with diabetes and preserved kidney function. JAMA. 290:2817-2823.
66. Herold, K.C., et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346:1692-1698.
67. Steele, C., et al. 2004. Insulin Secretion in Type 1 Diabetes. Diabetes. 53:426-433.
68. Boggi, U., et al. 2004. A benefit-risk assessment of basiliximab in renal transplantation. Drug Saf. 27:91-106.
69. Penn, I. 2000. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 23:101-113.
70. Couzin, J. 2003. Clinical trials. Diabetes' brave new world. Science. 300:1862-1865.
71. Montori, V.M., et al. 2002. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 25:583-592.
72. Davani, B., et al. 2004. Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Diabetes. 53(Suppl. 1):S51-S59.
73. Delaunay, F., et al. 1997. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest. 100:2094-2098.
74. Bloom, R.D., et al. 2002. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J. Am. Soc. Nephrol. 13:1374-1380.
75. First, M.R., Gerber, D.A., Hariharan, S., Kaufman, D.B., and Shapiro, R. 2002. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation. 73:379-386.
76. Weir, MR., and Fink, J.C. 1999. Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am. J. Kidney Dis. 34:1-13.
77. Lopez-Talavera, J.C., et al. 2004. Heparocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology. 145:467-474.
78. Bhargava, R., et al. 2004. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes. 53:1311-1317.
79. Hirshberg, B., Mog, S., Patterson, N., Leconte, J., and Harlan, D.M. 2002. Histopathological study of intraheparic islets transplanted in the nonhuman primate model using Edmonton protocol immunosuppression. J. Clin. Endocrinol. Metab. 87:5424-5429.
80. Markmann, J.F., et al. 2003. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival? Diabetes. 52:1591-1594.
81. Owen, R.J., et al. 2003. Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects. Radiology. 229:165-170.
82. Clouston, A.D., and Powell, E.E. 2004. Nonalcoholic fatty liver disease: is all the fat bad? Intern. Med. J. 34:187-191.
83. Casey, J.J., et al. 2002. Portal venous pressure changes after sequential clinical islet transplantation. Transplantation. 74:913-915.
84. Han, D., et al. 2004. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes. 53:2281-2290.
85. Ryan, E.A., et al. 2004. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 53:955-962.
86. Cryer, P.E. 2004. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N. Engl. J. Med. 350:2272-2279.
87. Ruggies, J.A., Kelemen, D., and Baron, A. 2004. Emerging therapies: controlling glucose homeostasis, immunotherapy, islet transplantation, gene therapy, and islet cell neogenesis and regeneration [review]. Endocrinol. Metab. Clin. North Am. 33:239-252, xii.